



Press Release

Germany's most innovative medium-sized companies: MLL Munich Leukemia Laboratory with successful placement

Result of the study "Innovation Champions 2023" sees the MLL Munich Leukemia Laboratory in the top positions

Munich, 05.09.2023 - The MLL Munich Leukemia Laboratory is one of the 100 most innovative medium-sized companies in Germany, according to the results of the "Innovation Champions 2023" study conducted by the management consultancy Munich Strategy on behalf of WirtschaftsWoche.

"Digitalization, automation and networking in healthcare: These are key topics that we at the MLL Munich Leukemia Laboratory as an innovative and forward-looking company in diagnostics, research and therapy are pursuing in a targeted manner for the benefit of our patients and partners," explains MLL Managing Director Prof. Dr. med. Dr phil. Torsten Haferlach. "Only recently, we already ranked first and received the TOP 100 label for special innovative strength and above-average innovation success in German medium-sized companies. The fact that we are now once again in the top positions in another ranking makes us very happy and proves that MLL and its entire team are on the right track."

Munich Strategy's consultants analyzed more than 4,000 German companies with annual sales of between 10 million and 1 billion euros. The 100 "Innovation Champions 2023" were selected from 400 finalists who stand out as industry leaders and through current innovations - the MLL Munich Leukemia Laboratory immediately landed in 4th place out of 100 and is also the best-placed company from the healthcare sector.

The basis for the final selection is an 'innovation score', two-thirds of which is calculated from the innovative strength and one-third from the performance of the companies. To determine innovative strength, the extent to which companies are characterized by continuous innovations ("innovation vitality"), whether they are classified as innovative by the market and competitors ("innovation perception") and whether they invest sustainably in innovations ("R&D & tech power") were examined. Performance is calculated from sales growth, earnings ratio and EBIT growth over the last four years.

"According to the study authors, the most innovative medium-sized companies are characterized by a holistic understanding of innovation as an integral part of their business model," says Haferlach. "We fully subscribe to this - also with regard to our technologies, processes and the thinking of our employees."

The results of the ranking were published in the media on August 11, 2023, cf.:

<https://www.wiwo.de/unternehmen/mittelstand/exklusives-wiwo-ranking-die-innovativsten-mittelstaendler-2023/29322674.html>

Press contact

MLL Münchner Leukämielabor GmbH, Corporate Communications, Max-Lebsche-Platz 31, 81377 Munich, Germany
Tel. +49 (0)89 99017 547, Mail: presse@mll.com; www.mll.com

MLL Munich Leukemia Laboratory GmbH

MLL Münchner Leukämielabor GmbH is a nationally and internationally operating laboratory for the diagnosis of leukemia and lymphoma. The expertise, quality assurance and turnaround time anchored in the company guarantee optimal examination procedures for the suspected diagnosis of leukemia or lymphoma. The modern equipment and the analysis methods at the latest scientific level enable optimal diagnostics for patients. The Munich Leukemia Laboratory is considered a world leader in terms of the breadth of its diagnostic portfolio. The combination of the interlocking methods of cytomorphology, chromosomal analysis, FISH, immunophenotyping and a variety of molecular genetic testing methods enables a comprehensive picture of the disease at hand to be established and, in the next step, to ensure optimally tailored medical treatment for patients.

Press contact

MLL Münchner Leukämielabor GmbH, Corporate Communications, Max-Lebsche-Platz 31, 81377 Munich, Germany
Tel. +49 (0)89 99017 547, Mail: presse@mll.com; www.mll.com